Begoña Mellado
Research group
- Translational genomics and targeted therapies in solid tumours Accredited researcher (R3A)
Featured publications
-
Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
Authors:Reference: BRITISH JOURNAL OF CANCER 2023. -
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Authors:Reference: NEW ENGLAND JOURNAL OF MEDICINE 2023. -
Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
Authors:Reference: NEW ENGLAND JOURNAL OF MEDICINE 2023. -
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Authors:Reference: ANNALS OF ONCOLOGY 2023. -
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
Authors:Reference: J Clin Oncol . 2023. -
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
Authors:Reference: EUROPEAN JOURNAL OF CANCER 2022. -
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Authors:Reference: JAMA Oncology 2022. -
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
Authors:Reference: NATURE MEDICINE 2022. -
Glutamine and cholesterol plasma levels and clinical outcomes of patients with metastatic castration-resistant prostate cancer treated with taxanes
Authors:Reference: Cancers 2021. -
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment
Authors:Reference: EUROPEAN UROLOGY 2021.
